Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.

Jingyu Zhu,Man Wang,Yang Yu,Huixin Qi,Kunkun Han,Juan Tang,Zubin Zhang,Yuanying Zeng,Biyin Cao,Chunhua Qiao,Hongjian Zhang,Tingjun Hou,Xinliang Mao

DOI: https://doi.org/10.18632/oncotarget.27350

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.2688.].

What problem does this paper attempt to address?

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Xia Li,Xiufeng Yin,Huafeng Wang,Jiansong Huang,Mengxia Yu,Zhixin Ma,Chenying Li,Yile Zhou,Xiao Yan,ShuJuan Huang,Jie Jin

DOI: https://doi.org/10.18632/oncotarget.27310

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14463.].
Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Xi Jiang,Chao Hu,Kyle Ferchen,Ji Nie,Xiaolong Cui,Chih-Hong Chen,Liting Cheng,Zhixiang Zuo,William Seibel,Chunjiang He,Yixuan Tang,Jennifer R. Skibbe,Mark Wunderlich,William C. Reinhold,Lei Dong,Chao Shen,Stephen Arnovitz,Bryan Ulrich,Jiuwei Lu,Hengyou Weng,Rui Su,Huilin Huang,Yungui Wang,Chenying Li,Xi Qin,James C. Mulloy,Yi Zheng,Jiajie Diao,Jie Jin,Chong Li,Paul P. Liu,Chuan He,Yuan Chen,Jianjun Chen

DOI: https://doi.org/10.1038/s41467-018-02947-0

IF: 16.6

2018-01-01

Nature Communications

Abstract:The original version of this Article contained an error in the spelling of the author James C. Mulloy, which was incorrectly given as James Mulloy. This has now been corrected in both the PDF and HTML versions of the Article.
A Novel Pi3k Inhibitor Identified by A High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma

Biyin Cao,Jingyu Zhu,Man Wang,Yang Yu,Huixin Qi,Kunkun Han,Zubin Zhang,Yuanying Zeng,Chunhua Qiao,Hongjian Zhang,Tingjun Hou,Xinliang Mao

DOI: https://doi.org/10.1182/blood.v124.21.4722.4722

IF: 20.3

2014-01-01

Blood

Abstract:The phosphatidylinositol-3-kinase (PI3K) has been developed as a promising target for the treatment of many cancers, including hematological malignancies, such as lymphoma, leukemia, and multiple myeloma (MM). Recent clinical trials have demonstrated Idelalisib, a specific PI3Kdelta inhibitor, reached a total 57% of response rate in relapsed indolent lymphoma and 72% of overall complete rate in relapsed chronic lymphocytic leukemia. MM remains fatal as a cancer of plasma cells because of lack of efficient drugs. Therefore, we tried to find novel PI3K inhibitors for MM therapy. To this end, we performed a high throughput virtual screen against 800,000 small molecule compounds using PI3Kγ as the analytic model and identified C98, a function unknown compound, as a potent inhibitor of PI3Ks. The cell-free enzymatic studies showed that C98 inhibited all class I PI3Ks at nano- or low micromolar concentrations but had no effects on AKT or mTOR activity. Molecular docking analysis revealed that C98 interfered with the ATP-binding pockets of PI3Ks by forming H-bonds and arene-H interactions with specific amino residues through which C98 specifically inhibited PI3K/AKT/mTOR signaling pathway, but had no effects on other kinases and proteins including IGF-1R, ERK, p38, c-Src, and STAT3. PTEN is a key negative modulator of the PI3K signaling pathway, but KIF did not show any induction of PTEN, thus further demonstrating that KIF is a selective PI3K inhibitor. Inhibition of PI3K by C98 led to myeloma cell apoptosis as shown activated caspase cascade signaling. Furthermore, oral administration of C98 delayed tumor growth in two independent human myeloma xenograft models in nude mice but did not show overt toxicity. Pharmacokinetic analysis revealed that C98 can be found in MM tissues at an average concentration up to 622.6 ng/g, suggesting that C98 can penetrate into the tumor tissues where it exerts its anti-myeloma activity. It also suggests C98 has a reliable oral activity. Therefore, through a high throughput virtual screen we identified a novel PI3K inhibitor that is orally active against multiple myeloma with great potential for further development.Disclosures No relevant conflicts of interest to declare.
Correction: A Novel Highly Potent Trivalent TGF-β Receptor Trap Inhibits Early-Stage Tumorigenesis and Tumor Cell Invasion in Murine Pten-deficient Prostate Glands

Tai Qin,Lindsey Barron,Lu Xia,Haojie Huang,Maria M. Villarreal,John Zwaagstra,Cathy Collins,Junhua Yang,Christian Zwieb,Ravindra Kodali,Cynthia S. Hinck,Sun Kyung Kim,Robert L. Reddick,Chang Shu,Maureen D. O'Connor-McCourt,Andrew P. Hinck,Lu-Zhe Sun

DOI: https://doi.org/10.18632/oncotarget.13343

2016-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.13343.].
Correction To: KIF5B-RET Fusion Kinase Promotes Cell Growth by Multilevel Activation of STAT3 in Lung Cancer

Yingying Qian,Shoujie Chai,Zuyu Liang,Yongfang Wang,You Zhou,Xia Xu,Chenchen Zhang,Min Zhang,Jingxing Si,Feiteng Huang,Zhangdan Huang,Wei Hong,Kai Wang

DOI: https://doi.org/10.1186/s12943-019-1093-0

IF: 37.3

2019-01-01

Molecular Cancer

Abstract:After the publication of this work [1],
Erratum: KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p: Erratum.

Mimi Zhou,Jinqiu Chen,Hui Zhang,Hailing Liu,Huan Yao,Xiaman Wang,Wanggang Zhang,Yingren Zhao,Nan Yang

DOI: https://doi.org/10.7150/ijbs.77067

2022-01-01

International Journal of Biological Sciences

Abstract:[This corrects the article DOI: 10.7150/ijbs.45999.].
Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Wei Wang,Bo Hu,Jiang-Jiang Qin,Jianwen Cheng,Xin Li,Mehrdad Rajaei,Jia Fan,Xin-Rong Yang,Ruiwen Zhang

DOI: https://doi.org/10.1016/j.gendis.2019.12.006

IF: 7.376

2019-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2019.06.001.].
Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Junfeng Zhang,Wei Xue,Kai Xu,Liang Yi,Yu Guo,Tian Xie,Haipeng Tong,Bo Zhou,Shunan Wang,Qing Li,Heng Liu,Xiao Chen,Jingqin Fang,Weiguo Zhang

DOI: https://doi.org/10.7150/thno.92042

IF: 11.6

2023-11-17

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.44427.].
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F -induced myeloproliferative neoplasms

Mengshi Hu,Tao Yang,Linyu Yang,Lu Niu,Jinbing Zhu,Ailin Zhao,Mingsong Shi,Xue Yuan,Minghai Tang,Jianhong Yang,Heying Pei,Zhuang Yang,Qiang Chen,Haoyu Ye,Ting Niu,Lijuan Chen

DOI: https://doi.org/10.1038/s41408-024-01058-y

IF: 9.812

2024-06-27

Blood Cancer Journal

Abstract:Blood Cancer Journal - Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms

oncology,hematology
Erratum: Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014;123(14):2204-2208

DOI: https://doi.org/10.1182/blood-2016-03-707646

IF: 20.3

2016-06-02

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2013-07-517136.].
Correction to: Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβkinase activity and interrupting NF-κB/COX-2-mediated signaling cascades

Xun Wang,Zhenlong Yu,Chao Wang,Wei Cheng,Xiangge Tian,Xiaokui Huo,Yan Wang,Chengpeng Sun,Lei Feng,Jinshan Xing,Yulong Lan,Dongdong Sun,Qingjuan Hou,Baojing Zhang,Xiaochi Ma,Bo Zhang

DOI: https://doi.org/10.1186/s13046-020-01699-4

2020-09-23

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology
Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Zexi Hu,Yong Hu,Xicheng Liu,Rongwen Xi,Aiqun Zhang,Deruo Liu,Qiang Xie,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.26252

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.5221.].
Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Zhongqing Zou,Tingting Guo,Jian Cui,Wenjiao Tang,Yan Li,Fangfang Wang,Tian Dong,Yunfan Yang,Yan Feng,Matthew Ho,Li Zhang,Ling Pan,Ting Niu

DOI: https://doi.org/10.7150/jca.79561

IF: 3.9

2022-01-01

Journal of Cancer

Abstract:[This corrects the article DOI: 10.7150/jca.53209.].

oncology
Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Yihui Zhou,Xiaomeng Gao,Yuan Meng,Bo Yang,Qiaojun He,Ji Cao

DOI: https://doi.org/10.3389/fphar.2021.785732

IF: 5.6

2021-01-01

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2021.748852.].
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Georg Lenz,Eliza Hawkes,Gregor Verhoef,Corinne Haioun,Soon Thye Lim,Dae Seog Heo,Kirit Ardeshna,Geoffrey Chong,Jacob Haaber,Wei Shi,Igor Gorbatchevsky,Susanne Lippert,Florian Hiemeyer,Paolo Piraino,Georg Beckmann,Carol Peña,Viktoriya Buvaylo,Barrett H. Childs,Gilles Salles

DOI: https://doi.org/10.1038/s41375-023-02133-2

2024-01-11

Leukemia

Abstract:Leukemia, Published online: 10 January 2024; doi:10.1038/s41375-023-02133-2 Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

oncology,hematology
Correction: Characterization of a small-molecule inhibitor targeting NEMO/IKKβ to suppress colorectal cancer growth

Zhenlong Yu,Jian Gao,Xiaolei Zhang,Yulin Peng,Wenlong Wei,Jianrong Xu,Zhenwei Li,Chao Wang,Meirong Zhou,Xiangge Tian,Lei Feng,Xiaokui Huo,Min Liu,Mingliang Ye,De-an Guo,Xiaochi Ma

DOI: https://doi.org/10.1038/s41392-023-01618-x

IF: 39.3

2023-09-05

Signal Transduction and Targeted Therapy

Abstract:Signal Transduction and Targeted Therapy, Published online: 04 September 2023; doi:10.1038/s41392-023-01618-x Correction: Characterization of a small-molecule inhibitor targeting NEMO/IKKβ to suppress colorectal cancer growth

biochemistry & molecular biology,cell biology
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Yunfu Deng,Guangzhi Ma,Karin A. Vallega,Dongsheng Wang,Mingliang Wang,Changwei Wang,Shaomeng Wang,Suresh S. Ramalingam,Shi-Yong Sun

DOI: https://doi.org/10.1038/s41417-022-00479-w

IF: 5.854

2022-05-10

Cancer Gene Therapy

Abstract:Cancer Gene Therapy, Published online: 10 May 2022; doi:10.1038/s41417-022-00479-w Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

Jiangsheng Xu,Yunhua Liu,Yujing Li,Hai Wang,Samantha Stewart,Kevin Van der Jeught,Pranay Agarwal,Yuntian Zhang,Sheng Liu,Gang Zhao,Jun Wan,Xiongbin Lu,Xiaoming He

DOI: https://doi.org/10.1038/s41565-019-0417-y

IF: 38.3

2019-01-01

Nature Nanotechnology

Abstract:The Supplementary Information originally published with this Article was an older version, in which ‘IFN-γ’ was misspelled ‘INF-γ’ in Supplementary Fig. 9 and the β-Actin blot in Supplementary Fig. 13 was the wrong image. The Supplementary Information has now been replaced.
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum

Libin Yan,Beichen Ding,Haoran Liu,Yangjun Zhang,Jin Zeng,Junhui Hu,Weimin Yao,Gan Yu,Ruihua An,Zhiqiang Chen,Zhangqun Ye,Jinchun Xing,Kefeng Xiao,Lily Wu,Hua Xu

DOI: https://doi.org/10.7150/thno.68810

IF: 11.6

2022-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.37628.].

medicine, research & experimental

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

A Novel Pi3k Inhibitor Identified by A High Throughput Virtual Screen Displays Potent Activity Against Multiple Myeloma

Correction: A Novel Highly Potent Trivalent TGF-β Receptor Trap Inhibits Early-Stage Tumorigenesis and Tumor Cell Invasion in Murine Pten-deficient Prostate Glands

Correction To: KIF5B-RET Fusion Kinase Promotes Cell Growth by Multilevel Activation of STAT3 in Lung Cancer

Erratum: KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p: Erratum.

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F -induced myeloproliferative neoplasms

Erratum: Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood. 2014;123(14):2204-2208

Correction to: Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβkinase activity and interrupting NF-κB/COX-2-mediated signaling cascades

Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Correction: Characterization of a small-molecule inhibitor targeting NEMO/IKKβ to suppress colorectal cancer growth

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer

Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: Erratum